Ophthalmology News
Regenera Drug Makes Eye Contact With Us
Friday April 8, 2005
DRUG developer Regenera will start receiving royalty income from next year after signing a licensing deal worth up to $US140 million ($A183 million) with a leading US ophthalmology company.